Radiopharmaceutical Isotopes

AMENDMENT TO SOLICITATION 36C25619Q0466
The purpose of this amendment is to address vendors questions. Below be find the vendors questions and the Government s response.
1. Question: If a company can only bid on SPECT or PET and not both, confirm that their response will be accepted.
Answer: Yes, if they can only supply one part of what is needed, their response can still be accepted.
2.           Question: You ve requested Sestimibi (generic of Cardiolite) which is a cardiac agent, are we able to quote Branded Cardiolite and/or Branded Myoview which are both cardiac agents used instead of a generic product.
Answer: Cardiolite is the brand name for Sestimibi and we want branded.
3.           Question: If there are products not listed, can a vendor add products to the Solicitation. Example - (UD PYP, UD Ceretec for Brain)
Answer: Yes
4.           Question: Clarify the start date of the Solicitation as 9/30/2019 for 6 months as there is also listed 5/1/2019 to 9/30/2019 listed further down the solicitation. Â
Answer: The start date will be the date of award (anticipating 5/1/19) to 9/30/19 for the base year. Each option year period will begin on 1 October for 12 months.
5. Question: Below are the PET specific products that do not come from a SPECT pharmacy that were a separate Solicitation in 2017.
Fludeoxyglucose F-18 FDG - PET Scan for wide range of oncology
100
Fluciclovine F-18 Axumin - PET Scan for Prostate Cancer
20
Gallium 68Â Ga68 - Dotatate - PET Scan for Neuroendocrine Tumors
15
Florbetapir F-18Â Amyvid - PET Scan for Alzheimer's detection
10
F-18 Sodium Fluoride (NaF) - PET Scan for skeletal imaging
      20
Answer: Currently the facility obtains PET products from a different pharmacy than the pharmacy they obtain SPECT or general products from. The PET products listed here are what we will be using..